23andMe Holding Co. announced on Monday that it will be reducing its workforce by approximately 40%, or 200 employees, as part of a restructuring initiative. Additionally, the company will halt all further development of its therapies. This move, though significant, is expected to result in annual savings of $35 million, which will help offset the one-time costs of about $12 million for severance and transition-related expenses. This major strategic shift effectively transforms 23andMe from a high-risk/high-reward biotech play into a
